Ischemic stroke: a paradoxical manifestation of cancer
| Autor: | Andrés F. Cardona, Ruth A. Salazar-Camelo, Hernán F. Bayona-Ortiz, Eder A. Moreno-Vargas |
|---|---|
| Přispěvatelé: | Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471] |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Malignancy Brain Ischemia 03 medical and health sciences Hypercoagulability 0302 clinical medicine Risk Factors Neoplasms medicine Humans Mortality Intensive care medicine Stroke Ischemic Stroke Cancer business.industry Hematology medicine.disease Prognosis 030104 developmental biology Increased risk Oncology Risk factors Blood biomarkers 030220 oncology & carcinogenesis Serological biomarkers Ischemic stroke business Complication |
| Zdroj: | Repositorio U. El Bosque Universidad El Bosque instacron:Universidad El Bosque |
| Popis: | Introduction Approximately 5–10 % of the patients with cryptogenic stroke have an underlying malignancy. Stroke as a complication of cancer increases the morbidity and mortality among cancer patients, leading to increased disability and healthcare costs. Objective To provide elements to guide physicians for when to suspect and evaluate for cancer in stroke patients. Development We performed a narrative review, portrayed in a question-answer format, to report relevant aspects of cancer stroke patients in the clinical practice and provide a guide based on the state-of-the-art literature. Conventional stroke mechanisms are only found in a fraction of patients with cancer. Although cardiovascular risk factors play an important role in both cancer and stroke pathogenesis, the recognition of more specific cancer-associated risk factors raises clinical suspicion for occult malignancy. We also expose the main type location and histology of tumors that are most commonly associated with stroke as well as potential blood biomarkers and current treatment considerations in the scenario of cancer associated stroke. Conclusion Subjects with active cancer are a patient population at increased risk for developing an ischemic stroke. Cryptogenic stroke patients have a higher risk of cancer diagnosis in the following 6–12 months. We recommend a multidisciplinary approach considering the high probability of a hidden malignancy and running a comprehensive evaluation including neurologic imaging, serological biomarkers and tight follow up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|